Acute dystonia induced by drug treatment

British Medical Journal

Volumn 319, Issue 7210, 1999, Pages 623-626

  Van Harten, Peter N ^a   Hoek, Hans W ^b   Kahn, Rene S ^c  

^a Psychiatric Center Zon and Schild   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; COCAINE; NEUROLEPTIC AGENT; PROCYCLIDINE; PROMETHAZINE;

ACUTE DISEASE; AGE; ANAMNESIS; DIFFERENTIAL DIAGNOSIS; DOCTOR PATIENT RELATION; DYSTONIA; GENDER; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MUSCLE SPASM; PATIENT POSITIONING; PRIORITY JOURNAL; SHORT SURVEY;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DYSTONIA; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 0033523432     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (34)

1. 1 Ca sey DE. Neuroleptic-indiced acute dystonia. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mount Kisco, NY: Futura, 1992:21-40.
2. 2 Casey DE. Neuroleptic-induced acute dystonia. In: Widiger TA, Frances AJ. Pincus HA, First MB, Ross R, Davis W, eds. DSM-IV source book. Vol 1. Washington, DC: American Psychiatric Association, 1994:545-59.
3. 3 Van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curaçao extrapyramidal syndromes study: J. Schizophr Res 1996;19:195-203.
4. 4 Van Harten PN, van Trier JCAM, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry 1998;59:128-30.
5. 5 Van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao extrapyramidal syndromes study: III. Am J Psychiatry 1998;155:565-7.
6. 6 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA, 1994.
7. 7 Aguilar EJ, Keshavan MS, Martin-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994;151:1819-21.
8. 8 Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991;148:85-9.
9. 9 Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40:1113-7.
10. 10 Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin Psychopharmcol 1987;7:342-5.
11. 11 Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:102-8.
12. 12 Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988;145:869-71.
13. 13 Arnt J, Skarsfeldt M. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
14. 14 Rupniak NMJ, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986;88:403-19.
15. 15 Volkow ND, Ruben CG, Wang G-J, Fowler JS, Moberg, PJ, Ding Y-S, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998;155:344-9.
16. 16 Mazurek MF, Rosebush PI. Corcadian pattern of acute, neuroleptic-induced dystonic reactions. Am J Psychiatry 1996;153:708-10.
17. 17 Johnson DAW. The side-effects of fluphenazine decanoate. Br J Psychiatry 1973;123:519-22.
18. 18 Benjamin S. Oculogyric crises. In: Joseph AB, Young RR, eds. Movement disorders in neurology and neuropsychiatry. Oxford: Blackwell, 1992:111-23.
19. 19 Lang AE. Psychogenic dystonia: a review of 18 cases. Can J Neurol Sci 1995;22:136-43.
20. 20 Zemishlany Z, Aizenberg D, Weiner Z, Weizman A. Artane abuse in schizophrenic patients. Int Clin Psychopharmacol 1996;11:199-202.
21. 21 Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ 1985;291:930-2.
22. 22 Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997;17:377-89.
23. 23 Sproule BA, Naranjo CA, Bremmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
24. 24 Lang AE. Miscellaneous drug-induced movement disorders. In: Lang AE, Waller WJ, eds. Drug-induced movement disorders. Mount Kisco, NY: Futura, 1992:339-81.
25. 25 Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord 1993;8:175-8.
26. 26 López-Alemany M, Ferrer-Tuset C, Bernacer-Alpera B. Akathisia and acute dystonia induced by sumatriptan. J Neurol 1997;244:131-3.
27. 27 Heath HW, Allen JK. Acute dystonia following standard doses of a cold medicine containing phenylpropanolamine. Clin Pediatr 1997;36:57-8.
28. 28 Priori A, Bertolasi L, Berardelli A, Manfredi M. Acute dystonic reaction to ecstasy. Mov Dis 1995;10:353.
29. 29 Horiguchi J, Inami Y. Effect of clonazepam on neuroleptic-induced oculogyric crisis. Acta Psychiatr Scand 1989;80:521-3.
30. 30 Gjerden P, Slordal L. Clinical pharmacology of anticholinergic antiparkinson agents: a review with emphasis on acute toxicity. Tidsskr Nor Laegeforen 1998;118:53-5.
31. 31 Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psyhiatry 1981;138:1243-4.
32. 32 Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizonphrenia. Am J Psychiatry 1988;145:1455-6.
33. 33 Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1992;149:511-3.
34. 34 Arana GW, Goff DC, Baldessarini RJ, Keepers GA. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988;145:993-6.